ACXP Acurx Pharmaceuticals, Inc.
$1.05▼ -3.67%
Healthcare
Other
Volume 52.2K
Avg Volume (10D) 60.1K
Key Metrics & Fundamentals
Market Cap
$5.74M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.05 - 7.54
% vs 50 MA
-18.01%
% vs 200 MA
-46.08%
RSI-14
29.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.79
Free Cash Flow
-$1.71M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.31M
COGS
–
Operating Exp
$2.31M
Operating Income
-$2.31M
EBIT
-$2.31M
Pretax Income
-$2.25M
Net Income
-$2.25M
EPS (Diluted)
-0.53
Price & Volume History
Loading chart…
Recent News
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
PR Newswire · Oct 26, 2026 8:01 AM ET
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
ACCESS Newswire · Oct 24, 2026 10:30 AM ET
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
PR Newswire · Oct 21, 2026 8:01 AM ET
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
ACCESS Newswire · Oct 5, 2026 1:25 PM ET
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
PR Newswire · Sep 29, 2026 8:01 AM ET
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
ACCESS Newswire · Sep 19, 2026 11:45 AM ET
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
PR Newswire · Sep 14, 2026 8:01 AM ET
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
GuruFocus.com · Aug 20, 2026 9:02 PM ET
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
PR Newswire · Aug 17, 2026 8:01 AM ET
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 12:56 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ACXP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.